DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/wzd9qr/protein) has announced the addition of the "2013 Report on the International Protein Engineering Market - Includes Forecast to 2017" report to their offering.
There are more than 200 protein-based products currently being marketed; 90% of them are used as therapeutics. In order to improve their clinical potential, second generation recombinants are being developed, each exhibiting improved efficiency and potency depending on their applications. The protein engineering market is driven by the need for drugs with improved efficiency and specificity, technological capabilities, rise of antibody based drugs, and steady growth in the therapeutic market. With growing incidences of cancer, autoimmune disorders, and infectious disease, spurt of new opportunities for growth of the market is expected by the end of this decade.
The use of monoclonal antibodies in therapeutics such as oncology, auto immune and inflammatory diseases are expected to increase during the forecast period. Chinas growing interest in research of monoclonal antibodies is expected to increase market share further. The market is likely to face competition from the entry of generics; however, with many therapeutic proteins in the pipeline, the market is expected to grow exponentially. Insulin analogs, which are more efficient than the recombinant insulin, are also a contributing factor for growth of the market.
Key Topics Covered:
2 Executive Summary
3 Protein Engineering Technologies - Landscape Analysis
5 Market Landscape Analysis
6 Geographic Analysis
6.1 North America
7 Technology And Product Portfolio
8 Competitive Landscape
8.2 Porter'S Five Force Analysis
8.3 Mergers & Acquisitions, 2009 - 2012
8.4 Partnerships & Collaborations, 2012 - 2013
8.5 New Product Launch, 2010 - 2012
9 Analyst Insights And Recommendation
10 Company Profiles
- Avidbiotics Corp.
- Biogen Idec.
- Bristol Myers Squibb Co.
- Eleven Biotherapeutics
- Eli Lilly & Co
- Glaxo Smithkline Plc
- Johnson & Johnson
- Merck & Co..
- Novartis Ag
- Regeneron Pharmaceuticals.
- Sigma-Aldrich Corp.
- Toolgen. (Korea)
- Xencor Inc.
For more information visit http://www.researchandmarkets.com/research/wzd9qr/protein